Does Network Health Cover Prolia?

What Is Prolia and Why Is Coverage So Often Questioned?

Prolia (denosumab) is a RANK ligand inhibitor that reduces osteoclast activity, slowing bone resorption. The FDA approved it in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and later expanded indications include glucocorticoid-induced osteoporosis, bone loss in men receiving androgen-deprivation therapy for prostate cancer, and bone loss in women receiving aromatase-inhibitor therapy for breast cancer [1]. Each 60 mg dose costs roughly $1,350 to $1,450 at wholesale acquisition cost, which makes it one of the more expensive osteoporosis treatments on the market and therefore a frequent target for insurer utilization management [2].

Coverage questions arise because Prolia does not sit in a retail pharmacy bin. It is a physician-administered biologic, which means it typically falls under medical benefits (Part B for Medicare enrollees) rather than pharmacy benefits, and patients often do not realize that two separate benefit structures may apply to the same drug depending on where and how it is administered [3]. Network Health is a Wisconsin-based insurer offering commercial HMO and PPO products as well as Medicare Advantage plans, and the rules governing Prolia differ meaningfully between those product lines.

The FREEDOM trial (N=7,868) demonstrated that denosumab reduced vertebral fracture risk by 68%, hip fracture risk by 40%, and non-vertebral fracture risk by 20% over 36 months compared with placebo [4]. That evidence base is strong enough that most major clinical guidelines, including those from the American Association of Clinical Endocrinology and the Endocrine Society, list denosumab as a second-line or high-risk first-line option for osteoporosis management [5].

How Network Health Evaluates Prolia Prior Authorization Requests

Prior authorization is required for Prolia on virtually every Network Health plan, both commercial and Medicare Advantage. The clinical criteria Network Health applies are broadly consistent with industry-standard utilization management benchmarks published by organizations such as the Institute for Clinical and Economic Review [6].

To obtain approval, your prescribing clinician typically must document at least one of the following:

• A DXA-measured bone mineral density T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip
• A T-score between -1.0 and -2.5 combined with a FRAX 10-year major osteoporotic fracture probability of 20% or higher, or a hip fracture probability of 3% or higher, per National Osteoporosis Foundation thresholds [7]
• A prior low-trauma (fragility) fracture regardless of T-score
• Intolerance to, or documented failure of, an adequate trial of an oral bisphosphonate (alendronate or risedronate for at least 12 months is a common insurer benchmark)
• An approved secondary indication such as glucocorticoid-induced osteoporosis while on prednisone 7.5 mg/day or equivalent for 3 or more months

The authorization request must include: a DXA report with numeric T-scores, a recent FRAX calculation printout, laboratory results ruling out secondary causes (serum calcium, vitamin D 25-OH, creatinine, TSH), and a summary of prior osteoporosis medication history [8].

A practical note: Network Health, like most regional insurers, requires that the PA request come from the administering provider, not just the referring physician. If your gynecologist diagnoses osteoporosis but your primary care office will actually give the injection, the PA must list the administering office as the requesting entity.

Medicare Advantage vs. Commercial Plan Differences at Network Health

The distinction between Medicare Advantage and commercial coverage matters more for Prolia than for almost any other osteoporosis drug, because Prolia's billing classification changes the benefit bucket it falls into [9].

Network Health Medicare Advantage plans. Prolia is covered under Part B when administered in a physician's office, outpatient hospital, or infusion center. The drug is billed using HCPCS code J0897. The patient's responsibility is typically 20% of the Medicare-approved amount after the Part B deductible ($240 in 2024). Some Network Health Medicare Advantage plans cap that 20% at a fixed dollar amount or waive the coinsurance entirely, so reviewing the Evidence of Coverage document for your specific plan year is necessary [10].

Network Health commercial HMO/PPO plans. Coverage is determined by whether the employer's group benefit design includes specialty drug coverage for physician-administered biologics. Most large-group commercial plans do include this, but some small-group and individual market plans exclude or severely limit biologic injectable coverage. The copay or coinsurance for a specialty-tier medical benefit drug can range from $50 to $500 per injection on commercial plans. Always call the member services number on the back of your insurance card and ask specifically about HCPCS code J0897 under your medical benefit.

The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women states directly: "Denosumab is recommended as an alternative anabolic or antiresorptive agent for women with postmenopausal osteoporosis who are at high risk of fracture, particularly those with renal insufficiency" [5]. That guideline language is useful to include in a prior authorization letter because it establishes that denosumab is a guideline-supported therapy, not an experimental one.

Step-by-Step: Getting Network Health to Approve Prolia

Coverage approval is not automatic, but a well-prepared submission dramatically shortens the timeline. Physicians in our clinical network report first-pass approval rates above 70% when all required documents are submitted together in the initial request [11].

Step 1. Confirm the DXA scan was performed at a facility that uses the International Society for Clinical Densitometry reference database and that the report includes both T-scores and Z-scores. A missing Z-score is a common reason for PA delay, not denial, but it adds weeks to the process.

Step 2. Calculate and print a FRAX score from the WHO Collaborating Centre tool at shef.ac.uk/FRAX. Include bone mineral density in the calculation if a DXA report is available [12].

Step 3. Document the bisphosphonate trial in a structured format: drug name, dose, duration, reason for discontinuation (GI intolerance, jaw concerns, atypical femur fracture risk, renal insufficiency with GFR <35 mL/min, etc.). A creatinine-based GFR <35 mL/min is an FDA-recognized contraindication to oral bisphosphonates, which is one of the clearest clinical justifications for skipping the step-therapy requirement [13].

Step 4. Submit all documents together through Network Health's prior authorization portal or fax line in a single transmission. Incomplete submissions are the leading cause of initial denials that are later overturned [6].

Step 5. Request a peer-to-peer review call immediately if an initial denial is issued. The treating physician speaking directly with the network's medical reviewer resolves the majority of clinical necessity denials without a formal appeal.

What to Do When Network Health Denies Prolia Coverage

A denial is not the end. Both state insurance regulations in Wisconsin and federal law under the ACA provide structured appeal pathways [14].

Level 1 internal appeal. Submit a written appeal within 60 days of the denial letter. Attach the FREEDOM trial full-text [4], the AACE/ACE 2020 postmenopausal osteoporosis clinical practice guidelines [15], and a letter from the treating physician explaining why the patient's specific clinical circumstances support Prolia over alternatives. If GFR is below 35 mL/min, include the laboratory report showing that value, because it is a hard contraindication to the bisphosphonates Network Health may prefer.

Level 2 external independent review. If the internal appeal is denied, Wisconsin law requires Network Health to offer an independent external review conducted by a reviewer unaffiliated with the insurer. External reviewers overturn insurer denials in a meaningful proportion of cases when clinical documentation is strong [14].

Expedited appeal. If a denial creates an urgent medical situation (for example, a patient who has already received one dose of denosumab faces a rebound increase in bone turnover markers and fracture risk if the second dose is delayed beyond 7 months), request an expedited appeal. Abrupt discontinuation of denosumab is associated with rapid bone mineral density loss and increased vertebral fracture risk within 12 months of stopping, a finding documented in the FREEDOM extension data [16].

This rebound phenomenon is clinically significant. The FDA updated Prolia's prescribing information to include language warning that multiple vertebral fractures have been reported after stopping denosumab, and that transitioning to an alternative antiresorptive agent upon discontinuation is recommended [1].

Patient Assistance and Cost Reduction Programs

Even when coverage is approved, out-of-pocket costs can be substantial. Several programs reduce or eliminate cost [17]:

Amgen ONE Support (formerly Prolia ONE Support). Amgen's manufacturer assistance program offers eligible commercially insured patients a copay card that may reduce out-of-pocket cost to as low as $0 per dose. Income limits and plan restrictions apply. Enrollment is available at amgensupportive.com or by calling 1-800-772-6436.

Amgen Safety Net Foundation. Uninsured or underinsured patients with household income at or below 500% of the federal poverty level may qualify for free drug through this foundation program.

Medicare Extra Help / Low Income Subsidy. This program does not apply to Prolia directly (since Prolia is a Part B drug, not Part D), but it reduces premiums and cost-sharing for the Medicare Advantage plan itself, which may indirectly lower the 20% coinsurance.

State Pharmaceutical Assistance Programs (SPAPs). Wisconsin's SeniorCare program provides a drug benefit to Wisconsin residents age 65 and older with income at or below 240% of the federal poverty level. While SeniorCare primarily covers Part D drugs, the supplemental wrap coverage on some plans can help with cost-sharing on Part B items. Confirming eligibility with the Wisconsin Department of Health Services is worthwhile [18].

Clinical Context: Who Actually Needs Prolia vs. Cheaper Alternatives?

Not every osteoporosis patient needs Prolia. Generic alendronate (Fosamax) costs under $15 per month at most pharmacies and reduces vertebral fracture risk by approximately 47% and hip fracture risk by approximately 51% in patients with a prior vertebral fracture, per the Fracture Intervention Trial (N=2,027) [19]. Risedronate and zoledronic acid (annual IV infusion) are other low-cost, guideline-supported options [15].

Prolia is particularly appropriate in specific clinical scenarios:

• GFR <35 mL/min, where oral bisphosphonates carry an FDA label contraindication [13]
• Demonstrated GI intolerance or esophageal disease precluding oral dosing
• Inability to remain upright for 30 minutes after dosing (neurologic or musculoskeletal limitations)
• Very high fracture risk (T-score <-3.0 or prior hip fracture) where anabolic therapy is not accessible and a maximally effective antiresorptive is needed
• Active androgen-deprivation or aromatase-inhibitor-induced bone loss, where denosumab has the largest evidence base [1]

The AACE/ACE guidelines grade denosumab as a Grade A, Evidence Level 1 recommendation for postmenopausal osteoporosis treatment, placing it at the same evidence level as oral bisphosphonates [15]. That parity is important when arguing for coverage in an appeal, because insurers cannot claim Prolia is investigational or without strong evidence support.

Alternatives Network Health May Prefer (and How to Counter Step-Therapy Requirements)

Network Health's formulary management, like that of most regional insurers, is structured to favor lower-cost options first. If your plan requires a bisphosphonate trial, understanding which exceptions apply allows your physician to document a valid bypass [20].

Alendronate 70 mg weekly is the most common first-step requirement. Risedronate 35 mg weekly or 150 mg monthly is the second most common. Ibandronate 150 mg monthly (oral) is sometimes listed but has weaker hip fracture evidence than the other two [15].

Valid step-therapy exceptions recognized by most insurers include:

• Renal insufficiency (GFR <35 mL/min)
• Barrett's esophagus, active esophagitis, or inability to swallow tablets
• Prior atypical femur fracture on a bisphosphonate
• Osteonecrosis of the jaw attributed to bisphosphonate use
• Prior bisphosphonate trial of 12 months or longer with continued bone loss documented on sequential DXA

Wisconsin's step-therapy override law (Wis. Stat. 632.867, effective 2018) requires insurers to grant a step-therapy exception within 72 hours (24 hours for urgent cases) when a clinician certifies that the required first-step drug is contraindicated, has previously been ineffective, or would cause an adverse reaction based on the patient's history [21]. Citing this statute in an appeal letter carries legal weight with Network Health as a Wisconsin-licensed insurer.

Monitoring Requirements That Affect Coverage Renewals

Network Health and most plans require reauthorization for Prolia every 12 months (covering two doses). Reauthorization submissions should include a repeat DXA scan, typically performed every 1 to 2 years per National Osteoporosis Foundation guidance [7], along with updated laboratory values and a clinical note confirming continued appropriateness of therapy.

One point that surprises many patients: if DXA shows bone mineral density has improved significantly and T-score has moved above -2.5, some insurers attempt to discontinue coverage on the grounds that the patient no longer meets the original criteria. This is clinically inappropriate. The FDA prescribing information and AACE guidelines note that discontinuing denosumab without transitioning to another antiresorptive agent leads to rapid bone loss and increased fracture risk [1, 15]. A reauthorization appeal should include this clinical rationale explicitly.

Serum bone turnover markers, specifically procollagen type 1 N-terminal propeptide (P1NP) and C-terminal telopeptide (CTX), can document ongoing pharmacologic effect and may be cited in reauthorization letters if DXA access is delayed [8].

Summary of Coverage Decision Factors

The probability that Network Health approves Prolia on first submission rises substantially when the following are all present in the initial PA packet: a DXA report with T-score at or below -2.5, a printed FRAX calculation, documentation of a prior bisphosphonate trial or a clear clinical contraindication to bisphosphonates, laboratory evidence of adequate calcium and vitamin D status, and a physician attestation letter citing AACE Grade A evidence for denosumab in the patient's specific clinical category [15]. Patients whose GFR is <35 mL/min have the strongest single-variable justification for bypassing step therapy entirely, since that value meets the FDA's own label contraindication for oral bisphosphonates [13].